Krinio Giannikou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krinio Giannikou has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- David J. Kwiatkowski
Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
11 shared publications - Joel Moss
Critical Care Medicine and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1590, USA
9 shared publications - Thomas N. Darling
Department of Dermatology, Uniformed Services University, Bethesda, MD 20814, USA
9 shared publications Alexander A. Goldberg
8 shared publications- Arnold S. Kristof
Department of Critical Care, Division of Pulmonary Medicine, McGill University Health Centre , Montréal, Québec H4A 0B1
8 shared publications Carole Doré
8 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Tables 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Figures and Supplementary Table Legends
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Supplementary Figures and Supplementary Table Legends
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose:The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma.Experimental Design:We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis.Results:We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism.Conclusions:In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose:The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma.Experimental Design:We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis.Results:We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism.Conclusions:In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 23 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5051-5069
Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose: The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma. Experimental Design: We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis. Results: We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism. Conclusions: In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- 23 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5051-5069
Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas
Purpose: The tumor microenvironment (TME) plays a vital role in cancer survival and progression and may play roles in drug resistance and immune escape. To date, few studies have detailed the TME of Ewing sarcoma. Experimental Design: We performed spatially resolved transcriptomics of primary treatment-naïve Ewing sarcoma tumor biopsies from patients with or without clinical metastasis, complemented by high-plex spatial proteomic analysis. Results: We discovered greater stromal enrichment in localized Ewing sarcoma primary tumors compared with metastasis-associated Ewing sarcoma primary tumors. Through spatial ligand–receptor analysis, we showed that the stroma-enriched regions harbor unique extracellular matrix–related cytokines, immune recruitment, and proinflammatory microenvironmental signals, implying that Ewing sarcoma stroma may play an antitumor role by acting as an immune recruitment center. All Ewing sarcoma tumors expressed protumorigenic macrophage migration inhibitory factor (MIF)–CD74 immune signaling connectivity, suggesting a potential immune-evasive mechanism. Conclusions: In addition to the immune recruitment role of tumor-associated stroma, our findings provide spatial insights into the TME of Ewing sarcoma and provide a rationale for the preclinical investigation of MIF as a potential target for Ewing sarcoma immunotherapy.
- Open Access
Integrated single-nuclei and spatial transcriptomic profiling of human sacrococcygeal teratomas reveals heterogeneity in cellular composition and X-chromosome inactivation
Sacrococcygeal teratomas (SCTs) are the most common neonatal tumors, yet their cellular origins, clinical stratification, and sex bias–occurring three times more in XX than XY individuals—remain poorly understood. To address these gaps, we examined six postnatal (one male and five female) and two prenatal (both female) SCTs by single nuclei RNA-seq and spatial transcriptomics. We identified five broad cellular lineages in SCTs: stroma, epithelia, endothelia, neuroectoderm, and immune. The transcriptomes and lineage compositions showed significant heterogeneity, which offer a framework for future molecular stratification. SCTs are thought to originate from and be propagated by pluripotent cells, notably however, we did not detect these populations. Among female tumors, a subset of cells exhibited biallelic expression of X-linked genes, consistent with X-inactivation failure or reactivation of the once inactivated X-chromosome. These biallelic cells were enriched for developmental and neuronal programs, whereas cells with single-allelic X-chromosome preferentially expressed immune-related genes. Biallelic X-chromosome activation, which can occur only in female cells, may result in transcriptomic features that favor survival of tumor cells, contributing to the sex bias of SCTs. Our findings reveal a link between X-chromosome inactivation and SCT cell identity, suggesting that X-dosage dysregulation may influence SCT heterogeneity and immune landscape.
Open AccessIntegrated single-nuclei and spatial transcriptomic profiling of human sacrococcygeal teratomas reveals heterogeneity in cellular composition and X-chromosome inactivation
Sacrococcygeal teratomas (SCTs) are the most common neonatal tumors, yet their cellular origins, clinical stratification, and sex bias–occurring three times more in XX than XY individuals—remain poorly understood. To address these gaps, we examined six postnatal (one male and five female) and two prenatal (both female) SCTs by single nuclei RNA-seq and spatial transcriptomics. We identified five broad cellular lineages in SCTs: stroma, epithelia, endothelia, neuroectoderm, and immune. The transcriptomes and lineage compositions showed significant heterogeneity, which offer a framework for future molecular stratification. SCTs are thought to originate from and be propagated by pluripotent cells, notably however, we did not detect these populations. Among female tumors, a subset of cells exhibited biallelic expression of X-linked genes, consistent with X-inactivation failure or reactivation of the once inactivated X-chromosome. These biallelic cells were enriched for developmental and neuronal programs, whereas cells with single-allelic X-chromosome preferentially expressed immune-related genes. Biallelic X-chromosome activation, which can occur only in female cells, may result in transcriptomic features that favor survival of tumor cells, contributing to the sex bias of SCTs. Our findings reveal a link between X-chromosome inactivation and SCT cell identity, suggesting that X-dosage dysregulation may influence SCT heterogeneity and immune landscape.
- 7 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (4) , 569-581
TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas
Aims: Although TSC1 or TSC2 inactivating mutations that lead to mTORC1 hyperactivation have been reported in hepatic angiomyolipomas (hAML), the role of other somatic genetic events that may contribute to hAML development is unknown. There are also limited data regarding the tumour microenvironment (TME) of hAML. The aim of the present study was to identify other somatic events in genomic level and changes in TME that contribute to tumorigenesis in hAML.Methods and results: In this study, we performed exome sequencing in nine sporadic hAML tumours and deep‐coverage targeted sequencing for TSC2 in three additional hAML. Immunohistochemistry and multiplex immunofluorescence were carried out for 15 proteins to characterise the tumour microenvironment and assess immune cell infiltration. Inactivating somatic variants in TSC2 were identified in 10 of 12 (83%) cases, with a median allele frequency of 13.6%. Five to 18 somatic variants (median number: nine, median allele frequency 21%) not in TSC1 or TSC2 were also identified, mostly of uncertain clinical significance. Copy number changes were rare, but detection was impaired by low tumour purity. Immunohistochemistry demonstrated numerous CD68+ macrophages of distinct appearance from Küpffer cells. Multiplex immunofluorescence revealed low numbers of exhausted PD‐1+/PD‐L1+, FOXP3+ and CD8+ T cells.Conclusion: hAML tumours have consistent inactivating mutations in TSC2 and have a low somatic mutation rate, similar to other TSC‐associated tumours. Careful histological review, standard IHC and multiplex immunofluorescence demonstrated marked infiltration by non‐neoplastic inflammatory cells, mostly macrophages.
- 7 September 2023
- Published by Wiley in Histopathology
- Vol. 83 (4) , 569-581
TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas
Aims: Although TSC1 or TSC2 inactivating mutations that lead to mTORC1 hyperactivation have been reported in hepatic angiomyolipomas (hAML), the role of other somatic genetic events that may contribute to hAML development is unknown. There are also limited data regarding the tumour microenvironment (TME) of hAML. The aim of the present study was to identify other somatic events in genomic level and changes in TME that contribute to tumorigenesis in hAML.Methods and results: In this study, we performed exome sequencing in nine sporadic hAML tumours and deep‐coverage targeted sequencing for TSC2 in three additional hAML. Immunohistochemistry and multiplex immunofluorescence were carried out for 15 proteins to characterise the tumour microenvironment and assess immune cell infiltration. Inactivating somatic variants in TSC2 were identified in 10 of 12 (83%) cases, with a median allele frequency of 13.6%. Five to 18 somatic variants (median number: nine, median allele frequency 21%) not in TSC1 or TSC2 were also identified, mostly of uncertain clinical significance. Copy number changes were rare, but detection was impaired by low tumour purity. Immunohistochemistry demonstrated numerous CD68+ macrophages of distinct appearance from Küpffer cells. Multiplex immunofluorescence revealed low numbers of exhausted PD‐1+/PD‐L1+, FOXP3+ and CD8+ T cells.Conclusion: hAML tumours have consistent inactivating mutations in TSC2 and have a low somatic mutation rate, similar to other TSC‐associated tumours. Careful histological review, standard IHC and multiplex immunofluorescence demonstrated marked infiltration by non‐neoplastic inflammatory cells, mostly macrophages.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file provides supplementary data pertaining to TSC2 mutation and protein expression analysis in human fibroblast cell lines (Figure S1); as well as Karyotypes (Figure S2), in vitro and in vivo pluripotency and differentiation potential (Figure S3), and genotyping mutation analysis (Figure S4) of human iPSC lines used in this study. Supplementary data regarding human-derived SMC lines, with and without TSC2 mRNA knock-down, specifically cell size analysis (Figure S5), gp100 and ER- expression (Figure S6) and cell death analysis (Figure S7), is also shown.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file provides supplementary data pertaining to TSC2 mutation and protein expression analysis in human fibroblast cell lines (Figure S1); as well as Karyotypes (Figure S2), in vitro and in vivo pluripotency and differentiation potential (Figure S3), and genotyping mutation analysis (Figure S4) of human iPSC lines used in this study. Supplementary data regarding human-derived SMC lines, with and without TSC2 mRNA knock-down, specifically cell size analysis (Figure S5), gp100 and ER- expression (Figure S6) and cell death analysis (Figure S7), is also shown.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file contains the full descriptive legends for Supplementary Figures S1-S7.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file contains the full descriptive legends for Supplementary Figures S1-S7.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file contains the full descriptive legends for Supplementary Figures S1-S7.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Human Pluripotent Stem Cell–Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis
This file contains the full descriptive legends for Supplementary Figures S1-S7.